HK Stock Market Move | CSPC PHARMA (01093) rose over 4% as SYS6010 was recently included in the list of breakthrough therapies by the National Medical Products Administration.

CSPC PHARMA (01093) rose over 4%, reaching an increase of 4.09% as of the time of this report, priced at HKD 9.545, with a trading volume of HKD 759 million. In the news, CSPC PHARMA announced that its developed product SYS6010 has recently been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) of China, with the proposed indication for recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC) in patients who have previously failed immunotherapy and platinum-based chemotherapy. This product has significantly improved the objective response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed prior immunotherapy and platinum-based chemotherapy, and the response is durable. Currently, a pivotal Phase III clinical trial is underway for this product as a monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed immunotherapy and platinum-based chemotherapy. Previously, this product had already received two breakthrough therapy designations granted by the NMPA (not including this one), with proposed indications being: monotherapy for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) that has failed EGFR-TKI and platinum-based chemotherapy; and for unresectable locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line treatment with platinum-based chemotherapy and immune checkpoint inhibitors (ICIs).